DSGN
NASDAQ · Biotechnology
Design Therapeutics Inc
$13.30
-0.30 (-2.21%)
Open$13.51
Previous Close$13.60
Day High$13.96
Day Low$12.95
52W High$17.25
52W Low$3.11
Volume—
Avg Volume741.0K
Market Cap880.64M
P/E Ratio—
EPS$-1.22
SectorBiotechnology
Analyst Ratings
Strong Buy
12 analysts
Price Target
+343.2% upside
Current
$13.30
$13.30
Target
$58.95
$58.95
$40.84
$58.95 avg
$77.34
Key Financials
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 133.74M | 128.39M | 127.15M |
| Net Income | -5,858,142 | -5,637,576 | -5,243,986 |
| Profit Margin | -4.4% | -4.4% | -4.1% |
| EBITDA | -5,607,781 | -6,075,682 | -5,861,844 |
| Free Cash Flow | -4,251,021 | -4,814,286 | -3,496,781 |
| Rev Growth | +7.4% | +3.0% | +5.7% |
| Debt/Equity | 0.91 | 1.04 | 0.96 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $201.55 | -0.57% | 88.1 | 372.29B |
| AMGN | Amgen Inc | $331.70 | +0.79% | 22.7 | 176.88B |
| GILD | Gilead Sciences Inc | $131.33 | -2.04% | 19.3 | 163.92B |
| VRTX | Vertex Pharmaceuticals Inc | $429.82 | +1.13% | 27.7 | 109.50B |
| REGN | Regeneron Pharmaceuticals | $714.89 | +0.82% | 16.5 | 74.30B |
| ALNY | Alnylam Pharmaceuticals Inc | $295.05 | -0.29% | 130.4 | 40.90B |